RESULTS SHOW COMPARABLE IMMUNOGENICITY OF FROZEN FLUMIST, LIQUID FORMULATION

MedImmune has announced that the primary objective was met in a Phase III study evaluating the immunogenicity of two different formulations of its live, attenuated intranasal influenza vaccine.

Preliminary results indicate that the currently approved frozen formulation, known as FluMist (Influenza Vaccine Live, Intranasal), and the investigational, next-generation refrigerator stable formulation, CAIV-T (cold adapted influenza vaccine, trivalent), produced similar immune responses.

Additional analyses of primary and secondary endpoints are ongoing and final results are expected to be submitted to the FDA later this year for review.